Orchestra BioMed Holdings, Inc.OBIONASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank74
3Y CAGR-10.6%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-10.6%/yr
Quarterly compound
Percentile
P74
Within normal range
vs 3Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 19.93% |
| Q3 2025 | 1.26% |
| Q2 2025 | 2.75% |
| Q1 2025 | 22.89% |
| Q4 2024 | -5.38% |
| Q3 2024 | 4.22% |
| Q2 2024 | 22.10% |
| Q1 2024 | 7.06% |
| Q4 2023 | -0.55% |
| Q3 2023 | 0.69% |
| Q2 2023 | 2.97% |
| Q1 2023 | 9.43% |
| Q4 2022 | 27.87% |
| Q3 2022 | 17.30% |
| Q2 2022 | 44.76% |
| Q1 2022 | -1.61% |
| Q4 2021 | -3.50% |
| Q3 2021 | 38.76% |
| Q2 2021 | -13.91% |
| Q1 2021 | 0.00% |